NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE12211 Query DataSets for GSE12211
Status Public on Jul 30, 2008
Title Gene expression of CML CD34+ cells during Imatinib therapy
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Imatinib has become the current standard therapy for patients with chronic myelogenous leukaemia (CML). For a better understanding of the Imatinib-related molecular effects in vivo, we assessed gene expression profiles of Philadelphia Chromosome positive (Ph+) CD34+ cells from peripheral blood of 6 patients with de novo CML in chronic phase. After 7 days of treatment with Imatinib the Ph+ CD34+ cells were reassessed to look for changes in the transcriptome. The expression level of 303 genes was significantly different comparing the transcriptome of the Ph+ CD34+ cells before and after 7 days of Imatinib therapy (183 down-regulated, 120 up-regulated, lower bound ≥1.2-fold). For a substantial number of genes governing cell cycle and DNA replication, the level of expression significantly decreased (CDC2, RRM2, PCNA, MCM4). On the other hand, therapy with Imatinib was associated with an increase of genes related to adhesive interactions, such as L-selectin or CD44. A group of 8 genes with differential expression levels were confirmed using a gene specific quantitative real-time PCR. Thus, during the first week of treatment, Imatinib is preferentially counteracting the bcr-abl induced effects related to a disturbed cell cycle and defective adhesion of leukemic Ph+ CD34+ cells.
 
Overall design In total 6 patients with new diagnosis CML (Chronic Myelogenous Leukemia) in chronic phase are inculded in the study. The gene expression profiles of the CD34+ hematopoietic stem and progenitor cells from the patients before first treatment with Glivec (Imatinib) are compared to the gene expression profiles of the CD34+ hematopoietic stem and progenitor cells of the same patients after 7 days of treatment with 400 mg Glivec / day.
 
Contributor(s) Bruennert DC, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F
Citation(s) 19052557
Submission date Jul 23, 2008
Last update date Dec 06, 2018
Contact name Daniela Bruennert
E-mail(s) Daniela.Bruennert@med.uni-duesseldorf.de
Phone 0211/8114869
Organization name University Clinic Duesseldorf
Department Clinic for Hematology, Oncology and clin. Immunology
Lab Haematologisches Forschungslabor
Street address Universitaetsstr. 1
City Duesseldorf
ZIP/Postal code 40225
Country Germany
 
Platforms (1)
GPL571 [HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array
Samples (12)
GSM307000 CML Patient 1 before therapy
GSM307012 CML Patient 2 before therapy
GSM307013 CML Patient 3 before therapy
Relations
BioProject PRJNA113723

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE12211_RAW.tar 22.7 Mb (http)(custom) TAR (of CEL, CHP)
Processed data included within Sample table
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap